Getting Started10 min readNovember 27, 2025

    Buy Tirzepatide in Seattle — $125/Month | Trimi Health

    GLP-1 weight loss treatment in Seattle — compounded tirzepatide shipped directly to your Seattle address in 2–3 business days. No clinic visits, no insurance required, just $125/month.

    Why Seattle Residents Choose Tirzepatide via Telehealth

    Tirzepatide — the active ingredient in Mounjaro and Zepbound — has emerged as one of the most effective weight loss medications ever studied. Clinical trials demonstrated approximately 22% body weight loss over 72 weeks, making it a powerful option for Seattle residents struggling with obesity. However, brand-name tirzepatide costs $1,000–$1,400 per month without insurance, and local Seattle clinics typically charge $400–800 per month for compounded versions.

    Trimi offers compounded tirzepatide at $125/month — delivered directly to any Seattle address through telehealth. No clinic visit, no insurance, no prior authorization. For Seattle residents, this represents a significant cost savings compared to both brand-name and clinic-based options.

    Seattle Tirzepatide Snapshot

    Population: ~740,000 city / ~4.0 million metro. Typical clinic cost: $400–800/mo. Brand Zepbound: $1,000–$1,400/mo. Trimi telehealth: $125/mo tirzepatide, $99/mo semaglutide.

    Learn more about how telehealth prescribing works, read our semaglutide vs. tirzepatide comparison, or explore Ozempic vs. Wegovy.

    Seattle Pricing: Trimi vs Local Providers & Pharmacies

    OptionMonthly CostIn-Person VisitInsurance Required
    Seattle Weight Loss Clinic (avg)$400–$800YesSometimes
    Seattle Pharmacy (brand Zepbound)$1,000–$1,400YesRecommended
    Trimi Telehealth (compounded)$125/mo (tirz) / $99/mo (sema)NoNo

    Interested in semaglutide instead? Read our detailed comparison to decide which medication is right for you.

    How It Works: 3 Steps to Get Tirzepatide in Seattle

    Step 1: Online Health Intake

    Complete a health questionnaire covering your medical history, medications, BMI, and weight loss goals — from anywhere in Seattle.

    Step 2: Provider Review & Prescription

    A licensed provider evaluates your submission, confirms candidacy for tirzepatide, and sends your prescription to a licensed compounding pharmacy.

    Step 3: Delivered to Your Seattle Door

    Temperature-controlled packaging arrives at your Seattle address within 3–5 business days. Monthly refills ship automatically.

    Check our GLP-1 candidacy guide to see if you qualify for tirzepatide.

    Available Medications for Seattle Residents

    Compounded Tirzepatide

    $125/month

    • Same active ingredient as Mounjaro/Zepbound
    • Dual GLP-1/GIP receptor agonist
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Learn about compounded medication safety, read about your first month of treatment, and check our GLP-1 weight loss timeline.

    Getting Started with Tirzepatide in Seattle

    Seattle residents with a BMI of 27+ (with a weight-related condition) or 30+ may qualify for tirzepatide treatment through Trimi. Whether you're in Fremont, Kirkland, or Tacoma or anywhere in the greater Seattle area, medication ships directly to your door.

    Read about managing GLP-1 side effects, explore our semaglutide vs. tirzepatide comparison, or see diet tips while on GLP-1 medications.

    Ready to Start Tirzepatide in Seattle?

    Get compounded tirzepatide delivered to any Seattle address for $125/month. No office visit, no insurance, no waiting room.

    Get Started for $125/Month

    Frequently Asked Questions: Tirzepatide in Seattle

    Can I get tirzepatide in Seattle without visiting a clinic?

    Yes. Trimi offers compounded tirzepatide entirely through telehealth. Seattle residents complete an online health intake, receive a provider evaluation, and get medication shipped directly to their Seattle address — no in-person visit required.

    How much does tirzepatide cost at Seattle weight loss clinics?

    Seattle-area weight loss clinics in neighborhoods like Capitol Hill, Bellevue, and Queen Anne typically charge $400–800 per month for compounded tirzepatide programs. Brand Zepbound costs $1,000–$1,400/month without insurance. Trimi delivers compounded tirzepatide for $125/month.

    How fast is tirzepatide shipping to Seattle?

    Most Seattle residents receive their compounded tirzepatide within 3–5 business days after prescription approval. Medication ships directly to your Seattle address — whether you're in Fremont, Kirkland, or Tacoma.

    What is the difference between tirzepatide and semaglutide?

    Tirzepatide is a dual GLP-1/GIP receptor agonist, while semaglutide targets only GLP-1 receptors. Clinical trials showed tirzepatide produced approximately 22% body weight loss at 72 weeks compared to 15% for semaglutide at 68 weeks. Trimi offers both: semaglutide at $99/month and tirzepatide at $125/month for Seattle residents.

    Is telehealth prescribing for tirzepatide legal in Washington?

    Yes. Washington law permits licensed providers to conduct telehealth evaluations and prescribe medications including GLP-1 agonists like tirzepatide. Trimi connects Seattle residents with licensed providers who manage care entirely online.

    Is compounded tirzepatide the same as Mounjaro or Zepbound?

    Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound but is prepared by a licensed compounding pharmacy at a fraction of the brand-name cost. It is not an FDA-approved branded product but is legally prescribed under federal compounding regulations.

    Can I continue tirzepatide treatment if I move within the Seattle area?

    Yes. Because Trimi is a telehealth program, your care is tied to your account — not a clinic location. Whether you move within Seattle or to a nearby area like Redmond or Issaquah, your treatment continues without interruption.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Tirzepatide and semaglutide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

    Sources & References

    1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. King County Public Health Department. Community Health Assessment 2023.
    5. FDA Prescribing Information for Zepbound (tirzepatide) and Wegovy (semaglutide).

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    Start your GLP-1 journey — from $99/mo

    Get Started